Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1147 ARTÍCULOS , VIENDO DEL 571 AL 585

Network excitability dysfunction in Alzheimer's disease: insights from in vitro and in vivo models

Santos SF, Pierrot N, Octave JN.

Rev Neurosci. 2010;21(3):153-71. doi: 10.1515/revneuro.2010.21.3.153.

Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex

Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD, Gandy S.

J Neurosci. 2010 Sep 29;30(39):13110-5. doi: 10.1523/JNEUROSCI.3872-10.2010.

Transport of drugs across the blood-brain barrier in Alzheimer's disease

Nicolazzo JA, Mehta DC.

Ther Deliv. 2010 Oct;1(4):595-611. doi: 10.4155/tde.10.41.

Finding the right target for treating Alzheimer disease

Mandell BF.

Cleve Clin J Med. 2010 Oct;77(10):650. doi: 10.3949/ccjm.77b.10010.

A DNA methylation study of the amyloid precursor protein gene in several brain regions from patients with familial Alzheimer disease

Brohede J, Rinde M, Winblad B, Graff C.

J Neurogenet. 2010 Dec;24(4):179-81. doi: 10.3109/01677063.2010.503978. Epub 2010 Oct 4.

Assessment of potential measures in models of progression in Alzheimer disease

McLaughlin T, Buxton M, Mittendorf T, Redekop W, Mucha L, Darba J, Jonsson L, Lacey L, Leibman C.

Neurology. 2010 Oct 5;75(14):1256-62. doi: 10.1212/WNL.0b013e3181f6133d.

Health economics and health policy issues in Alzheimer's disease

Rapp T.

J Nutr Health Aging. 2010 Oct;14(8):630-2. doi: 10.1007/s12603-010-0308-2.

Alzheimer's disease: the strength of association of costs with different measures of disease severity

Mauskopf J, Racketa J, Sherrill E.

J Nutr Health Aging. 2010 Oct;14(8):655-63. doi: 10.1007/s12603-010-0312-6.

Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments

McNamee P, Vanoli A, Hutchings D, McKeith I, Bond J.

J Nutr Health Aging. 2010 Oct;14(8):664-8. doi: 10.1007/s12603-010-0313-5.

Generic and disease-specific measures of quality of life in patients with mild Alzheimer's disease

Bhattacharya S, Vogel A, Hansen ML, Waldorff FB, Waldemar G.

Dement Geriatr Cogn Disord. 2010;30(4):327-33. doi: 10.1159/000320588. Epub 2010 Oct 2.

Developmental exposure to lead and late life abnormalities of nervous system

Basha R, Reddy GR.

Indian J Exp Biol. 2010 Jul;48(7):636-41.

Phenserine efficacy in Alzheimer's disease

Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH.

J Alzheimers Dis. 2010;22(4):1201-8. doi: 10.3233/JAD-2010-101311.

The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment

Sabbagh MN, Malek-Ahmadi M, Kataria R, Belden CM, Connor DJ, Pearson C, Jacobson S, Davis K, Yaari R, Singh U.

J Alzheimers Dis. 2010;22(3):1015-21. doi: 10.3233/JAD-2010-101185.

Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1α antigens in the brain

Ariga T, Yanagisawa M, Wakade C, Ando S, Buccafusco JJ, McDonald MP, Yu RK.

ASN Neuro. 2010 Oct 4;2(4):e00044. doi: 10.1042/AN20100021.

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

Cappell J, Herrmann N, Cornish S, Lanctôt KL.

CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias